SCHEMBL19974811

SCHEMBL19974811

CC(C(O)C(=O)NCc1cccc(Cl)c1)N(C)C=O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MASP2 O00187 1/20 0.47
OPRM1 P35372 1/20 0.44
OPRL1 P41146 1/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
SLC2A1 P11166 1/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
APEX1 P27695 1/20 0.41
TSHR P16473 1/20 0.41
RECQL P46063 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 1/20 0.41
ADAM17 P78536 1/20 0.41
HDAC1 Q13547 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975435 0.87 MASP2 (0.46) MASP2OPRM1OPRL1ALDH1A1LMNA
SCHEMBL19975405 0.85 MASP2 (0.49) MASP2ALDH1A1LMNARXFP1L3MBTL1
SCHEMBL19975564 0.84 MASP2 (0.48) MASP2ALDH1A1LMNARXFP1SLC2A1
SCHEMBL19974714 0.83 MASP2 (0.43) MASP2OPRM1OPRL1ALDH1A1LMNA
SCHEMBL19974737 0.82 MASP2 (0.44) MASP2ALDH1A1LMNARXFP1SLC2A1
SCHEMBL19975237 0.81 MASP2 (0.53) MASP2ALDH1A1LMNARXFP1SLC2A1
SCHEMBL19975335 0.81 ALDH1A1 (0.48) MASP2ALDH1A1LMNARXFP1GAA
SCHEMBL19974952 0.81 ALDH1A1 (0.50) MASP2ALDH1A1LMNAAPEX1NPC1
SCHEMBL19974709 0.81 OPRM1 (0.46) MASP2OPRM1OPRL1ALDH1A1RXFP1
SCHEMBL19974738 0.81 MASP2 (0.49) MASP2RXFP1GAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C MASP2 1122/4885OPRM1 2692/4885OPRL1 1821/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C MASP2 862/4885OPRM1 2605/4885OPRL1 1762/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C MASP2 1122/4885OPRM1 2692/4885OPRL1 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.